08/04/2026
https://www.stocktitan.net/news/AVAI/
"Recent news has highlighted Avant’s joint venture with SGAustria Pte. Ltd. to form Insulinova, Inc., which is intended to develop cell-based therapies for type 1 and some insulin-dependent type 2 diabetes using insulin-producing cells combined with encapsulation technology. Other announcements cover the creation and progress of Klothonova, a 50/50 joint venture with Austrianova that is developing encapsulated Klotho-producing cell therapies for age-related conditions, including cardiovascular and neurodegenerative diseases."
Read the latest AVAI news on Avant Technologies, including joint ventures for diabetes and Klotho therapies, AI-based Vision AI updates, and corporate actions. Latest AVAI news updated today, April 7.